Unity Biotechnology Announced Design Of Its Phase 2B Aspire Clinical Trial For UBX1325 (Foselutoclax) Head-to-head Against Aflibercept In Previously Treated Patients With Active Diabetic Macular Edema; First Patient Is Expected To Be Dosed In Q4 Of 2023
Portfolio Pulse from Benzinga Newsdesk
Unity Biotechnology announced the design of its Phase 2B ASPIRE clinical trial for UBX1325 (Foselutoclax) to be conducted head-to-head against Aflibercept in previously treated patients with active diabetic macular edema. The first patient is expected to be dosed in Q4 of 2023.
June 21, 2023 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Unity Biotechnology's announcement of the Phase 2B ASPIRE clinical trial design for UBX1325 may generate investor interest and potentially impact the stock price.
The announcement of the Phase 2B ASPIRE clinical trial design for UBX1325 is a significant milestone for Unity Biotechnology. This news may generate investor interest and potentially impact the stock price in the short term, as it demonstrates progress in the company's pipeline and potential future revenue streams.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100